Company news
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news
Ionis Pharmaceuticals, Inc. news releases on 6ix. Latest, Jan 26, 2023: Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize…
Press releases — page 4
Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research
January 25, 2023
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
January 8, 2023
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
January 8, 2023
Ionis to present at 41st Annual J.P. Morgan Healthcare conference
January 3, 2023
Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
December 4, 2022
Ionis partners with Metagenomi to add gene editing to its broad technology platform
November 13, 2022
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
November 12, 2022
Ionis reports third quarter financial results
November 8, 2022
Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
November 7, 2022
Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
November 6, 2022
Ionis announces positive results from fesomersen development program
November 3, 2022
Ionis to hold third quarter 2022 financial results webcast
October 25, 2022
Ionis announces plan for new manufacturing facility in Oceanside, Calif.
October 11, 2022
Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
September 22, 2022
Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis
September 6, 2022
Ionis reports second quarter financial results and recent business achievements
August 8, 2022
Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
July 27, 2022
Ionis to hold second quarter 2022 financial results webcast
July 26, 2022
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
July 25, 2022
Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
July 19, 2022
Ionis to participate in virtual fireside chat at H.C. Wainwright 1st Annual Hereditary Angioedema Conference
July 12, 2022
Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
July 10, 2022
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
June 24, 2022
Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
June 20, 2022
Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
June 12, 2022
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
June 2, 2022
Ionis to present at RBC Capital Markets Global Healthcare Conference
May 11, 2022
Ionis reports first quarter financial results and recent business achievements
May 3, 2022
Ionis to host 2022 virtual Annual Meeting of Stockholders
May 1, 2022
Ionis to hold first quarter 2022 financial results webcast
April 19, 2022
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
April 3, 2022
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
March 27, 2022
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
March 15, 2022
Ionis calls for applications for Janice Wiesman Young Investigator Grant Program
March 6, 2022
Ionis to present at the Cowen Annual Health Care Conference
February 28, 2022
Ionis reports fourth quarter and full year 2021 financial results and recent business achievements
February 23, 2022
Ionis to hold full year 2021 financial results webcast
February 9, 2022
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
January 30, 2022
Ionis announces eplontersen receives orphan drug designation from U.S. FDA
January 23, 2022
Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategy
January 18, 2022
Ionis to present at 40th Annual J.P. Morgan Healthcare conference
January 4, 2022
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
January 3, 2022
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
January 3, 2022
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
December 28, 2021
Ionis and AstraZeneca to develop and commercialize eplontersen
December 6, 2021
Ionis to hold virtual investor day event
December 1, 2021
Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen
November 23, 2021
Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema
November 17, 2021
Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021
November 11, 2021
Ionis to present at upcoming virtual investor conferences
November 8, 2021